Search results for "Finasteride"

showing 7 items of 7 documents

Antibody-Capped Mesoporous Nanoscopic Materials: Design of a Probe for the Selective Chromo-Fluorogenic Detection of Finasteride

2012

[EN] The synthesis of capped mesoporous silica nanoparticles (MSN) conjugated with an antibody (AB) as a gatekeeper has been carried out in order to obtain a delivery system able to release an entrapped cargo (dye) in the presence of a target molecule (antigen) to which the conjugated antibody binds selectively. In particular, MSN loaded with rhodamine B and functionalized on the external surface with a suitable derivative of N-(t-butyl)- 3-oxo-(5a,17b)-4-aza-androst-1-ene-17-carboxamide (finasteride) have been prepared (S1). The addition of polyclonal antibodies against finasteride induced capping of the pores due to the interaction with the anchored hapten-like finasteride derivative to g…

Detection limitINGENIERIA DE LA CONSTRUCCIONAqueous solutionChromatographyQUIMICA INORGANICANanotechnologyGeneral ChemistryMesoporous silicaFull PapersMCM-41finasterideMatrix (chemical analysis)chemistry.chemical_compoundQUIMICA ORGANICAchemistryQUIMICA ANALITICAhybrid materialsFinasterideRhodamine BantibodiesSelectivityMesoporous materialmolecular gatesChemistryOpen
researchProduct

5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

2020

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning ferti…

medicine.drug_classDermatologyReductasePharmacology030207 dermatology & venereal diseases03 medical and health sciences5 Alpha-Reductase Inhibitorchemistry.chemical_compound5-alpha Reductase Inhibitors0302 clinical medicinemedicineHumansTestosteronebusiness.industryFinasterideNeurotoxicityAlopeciaAndrogen AntagonistsGeneral MedicineDutasterideDutasteridemedicine.diseaseAndrogenchemistry030220 oncology & carcinogenesisDihydrotestosteroneFinasteridebusinessmedicine.drugDermatologic Therapy
researchProduct

Anti-androgens for the treatment of hirsutism.

2002

Many alternatives exist for treating hirsutism. Based on an analysis of scientific literature and on the experiences of the author, the most common anti-androgen agents are discussed in this review. Androgen receptor blockers (cyproterone acetate, flutamide and spironolactone), 5 alpha-reductase inhibitors (finasteride) and androgen-suppressing agents (gonadotrophin-releasing hormone [GnRH] agonists, oestroprogestins, corticosteroids and insulin-sensitising agents) are evaluated and compared. The importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed.

medicine.medical_specialtyCholestenone 5 alpha-ReductaseHirsutismAnti-Androgenurologic and male genital diseasesFlutamideGonadotropin-Releasing Hormonechemistry.chemical_compoundInternal medicineAndrogen Receptor AntagonistsMedicineHumansPharmacology (medical)Androgen Receptor AntagonistshirsutismPharmacologybusiness.industryCyproterone acetateAndrogen AntagonistsGeneral Medicinemedicine.diseaseAndrogen receptorEndocrinologyTreatment OutcomechemistrySpironolactoneFinasterideAndrogensFemalebusinessOxidoreductasesExpert opinion on investigational drugs
researchProduct

A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women

2002

Summary objectives To compare the relative effectiveness of two newer antiandrogens (flutamide and finasteride) with cyproterone acetate (CPA), at both low and high doses in the treatment of moderate to severe acne in hyperandrogenic women. subjects and design Forty-eight hyperandrogenic women were prospectively randomized to the following treatments for 1 year: CPA 2 mg with 35 µg ethinylestradiol; CPA 50 mg with 25 µg ethinylestradiol (reverse sequential regimen); flutamide 250 mg daily; and finasteride 5 mg daily. Assessment of Cook scores was the primary end-point of the trial. Blood for androgens was obtained at baseline in these women and 30 ovulatory age-matched controls. results Ser…

medicine.medical_specialtymedicine.drug_classbusiness.industryEndocrinology Diabetes and MetabolismHyperandrogenismCyproterone acetateAntiandrogenmedicine.diseaseFlutamidechemistry.chemical_compoundEndocrinologyEndocrinologychemistryEthinylestradiolInternal medicineFinasteridemedicineCyproteronebusinessAcnemedicine.drugClinical Endocrinology
researchProduct

Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-b…

2021

Background Acne is a chronic inflammatory skin disease which involves the pilosebaceous unit. Tissue inflammation isone of the crucial mechanisms, amongst others. Of the various cytokines, leukotriene B4 (LT-B4) is the most potentleucocyte chemotactic mediator. Montelukast is an antagonist of the LT-B4 receptor. Finasteride is an antiandrogen whichspecifically inhibits the 5α-reductase enzyme. Aims This study aimed at comparing the efficacy, tolerability and safety of montelukast versus finasteride in the treatmentof moderate acne in women. Patients/method This randomized, single-blinded, prospective trial over 12 weeks recruited 65 female subjects with moderate acne vulgaris (Global Acne G…

Cyclopropanesmedicine.medical_specialtymedicine.drug_classDermatologyAcetatesSulfidesAntiandrogenGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineAcne VulgarismedicineHumansProspective StudiesAdverse effectAcneMontelukastbusiness.industryFinasterideAntagonistmedicine.diseasechemistryTolerabilityFinasterideQuinolinesFemalebusinessmedicine.drugJournal of cosmetic dermatologyREFERENCES
researchProduct

Treatment of hyperandrogenic alopecia in women

2003

Many women with androgenic alopecia have normal circulating androgen levels. Increased scalp sensitivity to androgens may account for these cases. Even when androgen levels are increased, no particular pattern has emerged. Classical anti-androgen measures have proved disappointing, in contrast to the results obtained in women with hirsutism or acne. This study evaluated flutamide and finasteride in 36 premenopausal, hyperandrogenic women presenting with androgenic alopecia. Frontal hair thinning was assessed in photos of the frontoparietal region using the Ludwig grading system. Thirty ovulatory women matched for age and body weight served as a control group. Groups of 12 subjects received …

Adultmedicine.medical_specialtyRandomizationmedicine.drug_classDehydroepiandrosteroneEthinyl EstradiolAntiandrogenFlutamidelaw.inventionchemistry.chemical_compound5-alpha Reductase InhibitorsRandomized controlled triallawInternal medicineHumansMedicineTestosteroneEnzyme InhibitorsCyproterone AcetateTestosteronehirsutismGynecologyDehydroepiandrosterone Sulfatebusiness.industryFinasterideHyperandrogenismObstetrics and GynecologyCyproterone acetateAlopeciaAndrogen AntagonistsGeneral MedicineAndrogenmedicine.diseaseFlutamideRegimenEndocrinologyHair lossItalyLiverReproductive MedicinechemistryFinasterideCyproteroneFemaleHyperandrogenismbusinessmedicine.drugFertility and Sterility
researchProduct

Co-loading of finasteride and baicalin in phospholipid vesicles tailored for the treatment of hair disorders

2020

[EN] Hair loss affects a large number of people worldwide and it has a negative impact on the quality of life. Despite the availability of different drugs for the treatment of hair disorders, therapeutic options are still limited and scarcely effective. An innovative strategy to improve the efficacy of alopecia treatment is presented in this work. Finasteride, the only oral synthetic drug approved by Unites States Federal Drug Administration, was loaded in phospholipid vesicles. In addition, baicalin was co-loaded as an adjuvant. Their effect on hair growth was evaluatedin vitroandin vivo. Liposomes, hyalurosomes, glycerosomes and glycerol-hyalurosomes were manufactured by using a simple me…

medicine.medical_treatment02 engineering and technologyPharmacologyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivomedicineAnimalsGeneral Materials SciencePhospholipidsFlavonoidsLiposomeintegumentary systemChemistryVesicleFinasteride021001 nanoscience & nanotechnologymedicine.diseaseMice Inbred C57BLHair loss030220 oncology & carcinogenesisHair DisorderQuality of LifeFinasteride0210 nano-technologyAdjuvantBaicalin
researchProduct